Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.
About Cellectis
Cellectis (NASDAQ: CLLS) is a clinical-stage biopharmaceutical company at the forefront of gene-editing technologies, dedicated to developing innovative cancer immunotherapies and other therapeutic solutions. Leveraging over 18 years of expertise in genome engineering, Cellectis has established itself as a pioneer in the field, utilizing its proprietary TALEN® (Transcription Activator-Like Effector Nucleases) technology and PulseAgile electroporation system to create precise, next-generation therapies. These tools enable the company to harness the immune system's power to target and eliminate cancer cells effectively.
Core Focus: Allogeneic CAR-T and Gene-Edited HSPCs
Cellectis specializes in developing allogeneic Chimeric Antigen Receptor T-cells (UCART) for immuno-oncology applications. Unlike traditional autologous CAR-T therapies, which require harvesting and engineering a patient’s own cells, Cellectis’s allogeneic approach uses gene-edited donor cells. This innovation offers scalability, reduced manufacturing costs, and faster availability, making it a game-changer in cancer treatment. Additionally, the company is advancing gene-edited hematopoietic stem and progenitor cells (HSPCs) for therapeutic indications beyond oncology, showcasing its versatility in genome editing.
Proprietary Technologies
Cellectis’s competitive edge lies in its proprietary technologies:
- TALEN® Technology: A precise and versatile gene-editing tool that enables targeted modifications to DNA, ensuring high specificity and minimal off-target effects.
- PulseAgile Electroporation System: A cutting-edge delivery platform that enhances the efficiency of introducing genetic material into cells.
These technologies form the backbone of Cellectis’s product pipeline, enabling the development of innovative therapies that address unmet medical needs.
Market Position and Industry Context
Cellectis operates within the rapidly growing fields of immuno-oncology and precision medicine. The global demand for effective cancer therapies continues to rise, driven by advancements in biotechnology and an increasing understanding of the immune system's role in combating diseases. As a clinical-stage company, Cellectis focuses on research and development, with a pipeline of promising product candidates undergoing rigorous clinical trials. However, this stage also presents challenges, including regulatory approvals, high R&D costs, and competition from other biotech firms specializing in gene editing and CAR-T therapies.
Competitive Landscape
Key competitors in the gene-editing and CAR-T therapy space include CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics. Cellectis differentiates itself through its allogeneic approach, which offers significant advantages in scalability and cost-effectiveness. By addressing the limitations of autologous therapies, such as manufacturing complexity and patient-specific variability, Cellectis positions itself as a leader in next-generation cancer immunotherapies.
Challenges and Opportunities
While Cellectis’s innovative approach holds immense promise, the company faces several challenges. These include navigating a complex regulatory environment, managing high development costs, and competing in a crowded market. However, the potential rewards are substantial, with successful therapies offering transformative benefits for patients and significant market opportunities. The company’s focus on leveraging proprietary technologies and addressing unmet medical needs positions it well for long-term success.
Conclusion
Cellectis is a trailblazer in the biopharmaceutical industry, combining cutting-edge gene-editing technologies with a commitment to innovation in cancer immunotherapy and beyond. By leveraging its proprietary TALEN® technology and allogeneic approach, the company aims to revolutionize the treatment landscape, offering scalable, cost-effective solutions to some of the most pressing medical challenges. As a clinical-stage entity, Cellectis represents a high-risk, high-reward opportunity within the dynamic biotechnology sector.
Cellectis, a gene editing company listed on Nasdaq under the ticker CLLS, announced its share statistics as of July 31, 2021. The total number of shares in circulation is 45,465,310, while the total voting rights amount to 51,535,159. The company focuses on developing innovative CAR-T immunotherapies for oncology, utilizing their TALEN® gene editing technology and PulseAgile system. Cellectis aims to offer off-the-shelf gene-edited CAR T-cells and is dedicated to treating various cancers through its UCART product candidates.
Cellectis S.A. (NASDAQ: CLLS) will report its Q2 2021 and six-month financial results on August 5, 2021, after US market close. This will be followed by a conference call on August 6, 2021, at 8 AM EDT. Cellectis focuses on gene editing and CAR-T immunotherapies, aiming to develop off-the-shelf therapeutics for cancer. Their UCART products target various cancers and they are advancing their HEAL platform for blood disorders. The company is headquartered in Paris and has operations in New York and Raleigh.
Cellectis S.A. (NASDAQ: CLLS) announced it will release its financial results for Q2 and H1 2021 on August 6, 2021, after U.S. market close. A conference call will follow at 8:00 AM NY time, with dial-in numbers provided. The company specializes in genome editing and developing CAR-T cell therapies for cancer treatment. Cellectis aims to meet unmet medical needs through its innovative products and technologies, including its TALEN® genome editing and PulseAgile electroporation systems. The notice emphasizes Cellectis’ ongoing commitment to advancing therapies for patients.
Cellectis, a pioneering gene editing company, has reported a total of 45,461,310 shares and 51,531,339 voting rights as of June 30, 2021. The company is focused on developing innovative CAR-T immunotherapies for cancer treatment and therapeutic gene editing for various diseases. With over 21 years of expertise, Cellectis utilizes its proprietary technologies to advance hematological malignancies and blood disorders. It operates from its headquarters in Paris and additional locations in New York and Raleigh, with listings on both Nasdaq (ticker: CLLS) and Euronext Growth (ticker: ALCLS).
Cellectis announced the development of four new product candidates targeting solid tumors, including UCART20x22, a bi-specific CAR-T cell therapy for B-cell malignancies, and others for mesothelin, MUC1, and cancer-associated fibroblasts. The new .HEAL platform aims to address genetic diseases like Sickle Cell Anemia and lysosomal storage disorders. Additionally, Cellectis is enhancing its GMP manufacturing capabilities to increase production independence and control over gene therapy processes. The company is advancing multiple clinical trials, achieving significant patient enrollment and early positive results.
Cellectis, a clinical-stage biopharmaceutical company, focuses on pioneering allogeneic CAR-T immunotherapies. As of May 31, 2021, the company reported a total of 45,461,310 shares in circulation and 51,531,739 voting rights. Cellectis aims to develop life-saving UCART product candidates for cancers like AML, B-ALL, and MM, leveraging its TALEN® gene editing technology. The company's headquarters are in Paris, with operational sites in New York and Raleigh. Cellectis is listed on the Nasdaq (ticker: CLLS) and Euronext Growth (ticker: ALCLS).
Cellectis S.A. held its Annual Shareholders’ General Meeting on June 1, 2021, in Paris, with over 66% of voting rights exercised. Resolutions 1-24 passed, while Resolution 25 was rejected. The detailed voting results can be found on the company's website. Cellectis is pioneering allogeneic CAR-T therapies, focusing on off-the-shelf gene-edited CAR T-cells aimed at treating cancers like acute myeloid leukemia and multiple myeloma. The company is based in Paris, with additional offices in New York and Raleigh, and trades on Nasdaq under the symbol CLLS.
Cellectis S.A. (NASDAQ: CLLS) announced a partnership with Sanofi to supply alemtuzumab, an anti-CD52 monoclonal antibody, for use in Cellectis-sponsored UCART clinical trials. The CD52 knockout technology will allow UCART cells to resist alemtuzumab, enhancing T-cell persistence and expansion. Alemtuzumab will be integrated into lymphodepleting regimens for UCART22 in the BALLI-01 trial and UCART123 in the AMELI-01 trial. The agreement signifies a step toward a commercial supply relationship, aiming to drive progress in cancer therapies.
Cellectis announced key financial metrics as of April 30, 2021, revealing a total of 45,461,310 shares in capital and 51,526,159 voting rights. The company focuses on developing allogeneic CAR-T immunotherapies for cancer treatment, utilizing its proprietary gene editing technology, TALEN®. Cellectis aims to address unmet medical needs in cancers like acute myeloid leukemia and multiple myeloma, backed by over 21 years of expertise. The company is listed on the Nasdaq (ticker: CLLS) and Euronext Growth (ticker: ALCLS).
Cellectis S.A. (NASDAQ: CLLS) announced its Q1 2021 financial results, reporting a consolidated net loss of $12 million, or $0.28 per share, compared to a net income of $20 million in Q1 2020. Consolidated revenues decreased to $28 million from $52 million, mainly due to prior upfront payments. The cash position as of March 31, 2021, stood at $231 million, extending its cash runway into 2023. Ongoing clinical trials include BALLI-01 and AMELI-01, with a new collaboration with Cytovia Therapeutics for iPSC-derived NK cells. The company anticipates presenting further clinical data by year-end.
FAQ
What is the current stock price of Cellectis (CLLS)?
What is the market cap of Cellectis (CLLS)?
What does Cellectis specialize in?
How does Cellectis differentiate from competitors?
What are Cellectis’s proprietary technologies?
What challenges does Cellectis face?
What is the significance of allogeneic CAR-T therapies?
What market does Cellectis target?
Who are Cellectis’s main competitors?
What stage of development is Cellectis in?
